MJNA_Logo.png
Medical Marijuana, Inc. Subsidiary Kannaway® Announces Positive Preliminary Results of Validcare CBD Safety Study
May 18, 2022 09:00 ET | Medical Marijuana, Inc.
SAN DIEGO, CA, May 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
May 03, 2022 17:40 ET | Phathom Pharmaceuticals
VOQUEZNA TRIPLE and DUAL PAKs each contain vonoprazan, a novel, first-in-class potassium-competitive acid blocker (PCAB), and have demonstrated superior eradication rates vs. lansoprazole-based triple...
Logo.png
Biofrontera Inc. Announces FDA Approval of Biofrontera Pharma GmbH as a Contract Laboratory for Ameluz®
April 13, 2022 10:10 ET | Biofrontera Inc.
Significantly Improves Manufacturing Efficiency, Quality Control and Supply Reliability WOBURN, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical...
Berkshire Sterile achieves its first commercial drug approval by the FDA
March 22, 2022 10:00 ET | Berkshire Sterile Manufacturing
Lee, MA, March 22, 2022 (GLOBE NEWSWIRE) -- On March 1, 2022, a long-term client of Berkshire Sterile Manufacturing (BSM) announced the FDA approval of their Abbreviated New Drug Application (ANDA)...
5ef2af588104f70ce6d76d97_1.jpg
FDA Approves First COVID-19 Vaccine Which Can Be Distributed by Global WholeHealth Partners Corp (OTC: GWHP) as US Anticipates Considerable Uptick in Vaccination Rates, as Stated in 8K Filing 06/15/21
August 24, 2021 07:00 ET | Global WholeHealth Partners Corp.
SAN CLEMENTE, CA, Aug. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Global WholeHealth Partners Corp. (OTC: GWHP) is readying for sales due to the transition from Emergency Use Status to Full FDA...
logo.png
University of Calgary Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients
January 05, 2021 07:50 ET | Arch Biopartners
TORONTO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University of Calgary Cumming School of...
FDA Clearance Granted to WishBone Medical’s Pediatric External Fixation System
October 13, 2020 08:33 ET | WishBone Medical, Inc.
WARSAW, Ind., Oct. 13, 2020 (GLOBE NEWSWIRE) -- WishBone Medical, Inc., a leader in pediatric orthopedic medical devices, today announced it has received U.S. Food and Drug Administration (FDA)...
logo.jpg
ImCheck Achieves Initial Positive Independent Safety Review and Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01
September 10, 2020 05:46 ET | ImCheck Therapeutics SAS
ImCheck Achieves Initial Positive Independent Safety Reviewand Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01                        Company Receives FDA Approval for US IND ...
logo.png
Arch Biopartners Closes Non-Brokered Private Placement
June 30, 2020 09:21 ET | Arch Biopartners
TORONTO, June 30, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
logo.png
FDA Grants Arch Biopartners Permission to Proceed with Phase II trial to Evaluate Metablok (LSALT peptide) for the Treatment of COVID-19 patients
June 16, 2020 10:48 ET | Arch Biopartners
International, multi-center, randomized, double-blind, placebo-controlled clinical study targeting the prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury (AKI) in...